



# MDSCs in infectious diseases: regulation, roles, and readjustment

Anca Dorhoi<sup>1,2,3</sup> · Estibaliz Glaría<sup>4,5</sup> · Thalia Garcia-Tellez<sup>6</sup> · Natalie E. Nieuwenhuizen<sup>3</sup> · Gennadiy Zelinsky<sup>7</sup> · Benoit Favier<sup>8</sup> · Anurag Singh<sup>9</sup> · Jan Ehrchen<sup>10</sup> · Cornelia Gujer<sup>11</sup> · Christian Münz<sup>11</sup> · Margarida Saraiva<sup>12,13</sup> · Yahya Sohrabi<sup>14,15</sup> · Ana E. Sousa<sup>16</sup> · Peter Delputte<sup>17</sup> · Michaela Müller-Trutwin<sup>6</sup> · Annabel F. Valledor<sup>4,5</sup>

Received: 20 February 2018 / Accepted: 29 October 2018 / Published online: 19 December 2018  
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

## Abstract

Many pathogens, ranging from viruses to multicellular parasites, promote expansion of MDSCs, which are myeloid cells that exhibit immunosuppressive features. The roles of MDSCs in infection depend on the class and virulence mechanisms of the pathogen, the stage of the disease, and the pathology associated with the infection. This work compiles evidence supported by functional assays on the roles of different subsets of MDSCs in acute and chronic infections, including pathogen-associated malignancies, and discusses strategies to modulate MDSC dynamics to benefit the host.

**Keywords** Myeloid regulatory cells · MDSC · Infection · Immunosuppression · Oncogenic viruses · Mye-EUNITER

## Abbreviations

Arg	Arginase	JEV	Japanese encephalitis virus
Arm	Armstrong	<i>K. pneumoniae</i>	<i>Klebsiella pneumoniae</i>
ATRA	All-trans retinoic acid	<i>L. major</i>	<i>Leishmania major</i>
<i>B. fragilis</i>	<i>Bacteroides fragilis</i>	LCMV	Lymphocytic choriomeningitis virus
<i>C. albicans</i>	<i>Candida albicans</i>	LOX	Lipoxygenase
C13	Clone 13	Mφ	Macrophage
CCR	C-C Chemokine receptor	M-MDSC	Monocytic MDSC
COST	European Cooperation in Science and Technology	<i>M. tuberculosis</i>	<i>Mycobacterium tuberculosis</i>
EBV	Epstein Barr virus	MR	Mannose receptor
ETBF	Enterotoxigenic <i>Bacteroides fragilis</i>	MRC	Myeloid regulatory cell
FV	Friend virus	mTOR	Mammalian target of rapamycin
<i>H. felis</i>	<i>Helicobacter felis</i>	NADPH	Nicotinamide adenine dinucleotide phosphate
<i>H. polygyrus</i>	<i>Heligmosomoides polygyrus</i>	NOS	NO synthase
HbsAg	HBV surface antigen	<i>P. aeruginosa</i>	<i>Pseudomonas aeruginosa</i>
HDT	Host-directed therapy	PcP	<i>Pneumocystis pneumonia</i>
IAV	Influenza A virus	PDE	Phosphodiesterase
iNKT	Invariant NK T	PGE2	Prostaglandin E2
		PMN-MDSC	Neutrophil-like MDSC
		ROS	Reactive oxygen species
		<i>S. aureus</i>	<i>Staphylococcus aureus</i>
		SIV	Simian immunodeficiency virus
		<i>T. crassiceps</i>	<i>Taenia crassiceps</i>
		<i>T. cruzi</i>	<i>Trypanosoma cruzi</i>
		<i>T. gondii</i>	<i>Toxoplasma gondii</i>
		TB	Tuberculosis
		Tfh	T Follicular helper

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s00262-018-2277-y>) contains supplementary material, which is available to authorized users.

✉ Anca Dorhoi  
anca.dorhoi@fii.de

✉ Annabel F. Valledor  
afernandezvalledor@ub.edu

Extended author information available on the last page of the article

## Introduction

Myeloid cells recognize pathogens and orchestrate the development of antimicrobial immunity. The sensing of microbial cues initiates inflammatory responses during infectious diseases. These events contribute to the generation of effective adaptive immune responses, pathogen removal, and a return to homeostasis. However, if uncontrolled or unresolved, inflammation results in immunopathology. Pathogen-derived molecules and inflammatory mediators trigger expansion and/or activation of specific myeloid cell subsets with regulatory activities, termed myeloid regulatory cells (MRCs). This affects the disease outcome in different ways, depending on the type and stage of the infection. MRCs include MDSCs with either a monocytic (M-MDSC) or a neutrophilic (PMN-MDSC) phenotype, alternatively activated macrophages, and regulatory dendritic cells. Here, we focus specifically on the functions of MDSCs in acute and chronic infections, including diseases triggered by oncogenic microbes.

It is important to note that there are limitations to the ways in which the functions of MDSCs can be addressed experimentally. Knockout animals specifically lacking MDSCs do not exist, as MDSCs are generated during the development of myeloid progenitor cells into innate immune cells such as neutrophils and monocytes. However, the potential functions of MDSCs have been explored using correlative and adoptive transfer studies, *ex vivo* functional assays and drug-induced differentiation of MDSCs. The identification of MDSCs is based on phenotypic markers and the validation of suppressive activity by immunological assays [1, 2]. Here, we will discuss the interactions of MDSCs with selected pathogens using examples in which MDSC subsets have been characterized using functional assays and not by immunophenotyping techniques alone. We will highlight the relevance of MDSCs in the resolution of inflammation, their roles as reservoirs for persistent microbes, the microbial signatures and host pathways that regulate MDSC dynamics, the capacity of MDSCs to modulate immunopathology in chronic infections and the implications of this for microbial-induced carcinogenesis. Finally, we will address MDSC-targeted strategies and discuss how these could be employed to treat infectious diseases.

## Pathogen and host factors drive MDSC dynamics during infection

Experimental infections and *ex vivo* assays have indicated that selected pathogen-associated molecular patterns trigger the expansion of MDSCs. In mice, bacterial lipopeptides that bind TLR2/6 [3], LPS [4], which engages TLR4, and

flagellin [5], a TLR5 ligand, lead to local or systemic expansion of Gr1<sup>+</sup> CD11b<sup>+</sup> MDSCs with proven immunosuppressive properties *ex vivo* and *in vivo*. Viral ligands of TLR2, including HCV core protein [6–9] and HBV surface antigen (HbsAg) [10], both of which are secreted from infected hepatocytes, as well as surface HIV-1 gp120 [11], induce increased numbers of M-MDSCs that are able to suppress T cell [6–8, 10, 11] and NK cell responses [9]. Such PRR ligands can also drive differentiation of monocytes into MDSCs [12]. In contrast to TLR2/6, 4 and 5 ligands which lead to expansion of MDSCs, TLR3, 7 or 9 ligands negatively regulate the functionality of MDSCs during infection with influenza A virus (IAV) [13, 14].

Fungal pathogens promote the accumulation of PMN-MDSCs by activating C-type lectin receptors, notably the dectin-1/Card9 pathway [15]. However, purified  $\beta$ -glucans, which are abundant in *Candida* spp. and *Aspergillus* spp. and represent agonists for dectin-1, were shown to restrict MDSC expansion in tumor models [16]. For this reason, the precise molecular mechanisms by which fungal pathogens promote MDSC genesis require further characterization. Some parasite glycans also increase MDSC frequencies in infected tissues. For instance, intraperitoneal injections with intact glycans purified from *Taenia crassiceps* (*T. crassiceps*) or schistosome oligosaccharides elicit myeloid cell populations that suppress T-cell proliferation *in vitro* [17–19]. Some of these effects are independent of TLR4 and Th2-type cytokines [18, 19]. Moreover, immunization of mice with *Toxoplasma gondii* (*T. gondii*) oocyst lysate antigen leads to increased numbers of PMN-MDSCs in the lungs [20]. However, the host sensors that control MDSC accumulation in parasitic infections are unknown.

In addition to PRRs, many other host factors affect MDSC dynamics during infection. Several inflammatory mediators and growth factors, including VEGF, GM-CSF, G-CSF, IL-1 $\beta$ , IL-6, TNF- $\alpha$ , and prostaglandin E2 (PGE2), have been identified as inducers of MDSC expansion and/or activation [21–23]. There appears to be a critical requirement for IL-6 and STAT3 signaling in expansion of MDSCs in several unrelated infections [3, 10, 24, 25]. For example, a significant reduction in accumulation of splenic MDSCs was observed in IL-6-deficient mice during *Trypanosoma cruzi* (*T. cruzi*) infection in comparison with wild-type (WT) mice [24]. Similarly, mice with deficient hepatic expression of gp130, the common signaling receptor for the IL-6 family of cytokines, had reduced frequencies of MDSCs during polymicrobial sepsis [25]. Furthermore, the IL-6-induced hepatic acute-phase proteins serum amyloid A and chemokine (C-X-C motif) ligand (Cxcl)1 cooperatively promoted mobilization and peripheral accumulation of MDSCs [25].

The growth factors GM-CSF and G-CSF control myelopoiesis in the steady state. Dysregulated myelopoiesis

occurs when levels of these factors are increased long-term, particularly during chronic infections, and this leads to continuous activation of progenitors, promoting MDSC generation [23]. Recent findings indicate that GM-CSF drives the conversion of murine Ly6C<sup>hi</sup> monocytes and human CD14<sup>+</sup> monocytes into suppressor cells. This differentiation requires activation of the protein kinase B (PKB)/mammalian target of rapamycin (mTOR)/mTOR complex (mTORC)1 pathway by GM-CSF and subsequent signaling through the IFN- $\gamma$  receptor/IFN regulatory factor-1 (IRF-1) pathway [26]. Anti-apoptotic molecules such as cellular-Fllice-like inhibitory protein (c-FLIP) and myeloid leukemia cell differentiation protein (MCL-1) play a role in the generation of MDSCs during cancer [27], but their role in MDSC generation during infection has not been demonstrated. Overall, it seems that the growth factors and cytokines that are present during an infection may interfere with the physiological differentiation of hematopoietic progenitors and result in abnormal cell phenotypes, including MDSCs. The interaction of MDSCs with other immune cells during infection may also influence their frequency and suppressive capacity. An example is the increased expansion of MDSCs in mice deficient in invariant NK T (iNKT) cells compared to control mice during infection with IAV [13]. MDSC suppressive activity was abolished *in vivo* by adoptive transfer of iNKT cells, suggesting that the interaction between iNKT cells and MDSCs modulates MDSC suppressive activity, at least during IAV infection. Whether this pathway operates in other infections remains to be determined. In summary, accumulating evidence suggests that particular pathogen sensors and inflammatory mediators mutually or independently activate pathways that lead to the expansion of MDSCs during infection. Additional regulators and processes that affect MDSC dynamics will presumably be uncovered as research into the biology of these cells in infection develops.

### The outcome of MDSC expansion in acute infection

MDSC subsets appear to exacerbate certain acute infections (Supplementary Table 1) (Fig. 1). In viral diseases, expansion of MDSCs may favor immunosuppression and viral persistence. An example is the inhibition of T follicular helper cells (Tfh) and B cells by MDSCs that was observed during infection with a Japanese encephalitis virus (JEV) strain that causes acute encephalopathy [28]. Targeting MDSCs with retinoic acid reversed suppression and improved the survival of JEV-infected mice. In infection with Friend retrovirus (FV), which is able to persist lifelong in mice despite eliciting a strong acute immune response, expansion of both M-MDSC and PMN-MDSC populations during the late phase of acute

infection correlated with CD8<sup>+</sup> T-cell contraction. Of these MDSC subsets, experiments *in vitro* suggested that only PMN-MDSCs could suppress virus-specific CD8<sup>+</sup> T-cell responses [29], although the specific contribution of this subset was not evaluated *in vivo*. Depletion of MDSCs rescued activated CD8<sup>+</sup> T cells and minimized viral loads. These observations suggest that MDSCs interfere with immune control of the viral load during acute infection, facilitating the subsequent establishment or maintenance of viral chronicity. The expansion of MDSCs during acute toxoplasmosis, a parasitic infection, has also been partly associated with immune hyporesponsiveness within the lung [30].

The expansion of MDSCs may also facilitate disease progression during sepsis. The number of circulating PMN-MDSCs in septic patients correlates with the disease severity and with plasma levels of IL-6 [31]. The type of infection may influence the dynamics of different MDSC subsets, as M-MDSCs were found in all sepsis patients included in a study cohort, whereas PMN-MDSCs expanded preferentially in sepsis caused by Gram-positive bacteria. A CD14<sup>low</sup> PMN-MDSC population among the neutrophilic subset expressed IL-10 and suppressed T-cell proliferation *in vitro* through the production of reactive oxygen species (ROS) [32]. In a recent study in which patients were enrolled from intensive care units, PMN-MDSCs were specifically expanded in individuals with sepsis and were responsible for increased arginase (Arg) 1 activity [33]. High initial frequencies of PMN-MDSCs, but not of M-MDSCs, were associated with subsequent nosocomial infections. Depletion of CD15<sup>+</sup> cells from PBMCs obtained from sepsis patients increased the rate of T-cell proliferation *in vitro*, suggesting that PMN-MDSCs may have been largely responsible for the sepsis-induced immune suppression. The observations in murine models of sepsis diverge from those in the human studies. The expansion of MDSCs during polymicrobial sepsis induced by cecal ligation was found to be beneficial for the host [25, 34]. Murine MDSCs suppressed production of IFN- $\gamma$  by CD8<sup>+</sup> T cells and contributed to sepsis-induced Th2 polarization *in vivo* [34]. Mice with reduced levels of circulating and splenic MDSCs as a consequence of hepatic gp130 deficiency showed decreased survival after induction of polymicrobial sepsis. The phenotype could be reverted by the adoptive transfer of a heterogeneous population of Gr1<sup>+</sup>CD11b<sup>+</sup> cells comprised of 50% PMN-MDSCs [25]. Together, these studies support a host-protective anti-inflammatory role for MDSCs during polymicrobial infections in mice. The discrepancy between observations emerging from humans and murine models may stem from the analyses of distinct phases of sepsis as well as from the distinct features of the MDSC subsets involved.


MDSCs may also be beneficial for the host in certain acute pneumonias and parasitic infections. During infection with *Klebsiella pneumoniae* (*K. pneumoniae*) tight control of inflammation is critical for pathogen clearance [35]. The accumulation of neutrophils in non-resolving pneumonia causes collateral tissue damage, resulting in acute lung injury. In mice infected with *K. pneumoniae*, MDSCs were recruited to the lungs several days post challenge and represented an important local source of IL-10, which correlated with the resolution of inflammation and recovery after infection [35]. MDSCs were shown to efferocytose apoptotic neutrophils, limit inflammation, and prevent tissue damage, thereby facilitating the return to tissue homeostasis. In a murine model of Chagas disease, M-MDSCs exhibited protective roles as well. They were detected in myocardial lesions during the acute phase of *T. cruzi* infection and suppressed polyclonal T-cell proliferation *ex vivo* through a NO-dependent mechanism [36]. Furthermore, higher numbers of MDSCs were detected in BALB/c mice compared to C57BL/6 mice during infection, along with lower levels of inflammatory cytokines, reduced liver injury and increased resistance to infection [24]. Moreover, decreased MDSC recruitment in IL-6-deficient mice and MDSC depletion both led to increased inflammation, higher parasite burdens and mortality [24]. Thus, MDSC-mediated modulation of the inflammatory response during *T. cruzi* infection allowed efficient parasite clearance while simultaneously limiting overzealous adaptive immune responses and excessive tissue damage. In humans suffering from chronic Chagas disease, increased tyrosine nitration was detected on CD8<sup>+</sup> T cells and heightened NO production was shown in peripheral leukocytes [37]. Characteristics of MDSCs such as activation of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and production of NO and peroxynitrites can cause nitration of the TCR and may contribute to their suppressive activity in such conditions. However, whether MDSC expansion influences tyrosine nitration of CD8<sup>+</sup> T cells in humans with Chagas disease remains to be established. Overall, MDSC activity in acute infections can culminate in negative or beneficial outcomes, depending on the microorganism involved as well as the pattern and extent of inflammation. Deleterious effects could result from inability of the host to clear pathogens because of immunosuppression, whereas suppression of inflammatory responses that exacerbate tissue damage could be beneficial to the host.

## The versatile roles of MDSCs in chronic infection

Many successful pathogens manipulate host immunity by suppressing T-cell responses, thereby establishing chronic infections. Chronicity poses dual risks. First, it requires prolonged therapy, which often leads to poor patient compliance

and the development of antimicrobial resistance. Second, it leads to tissue remodeling and the development of microenvironments that favor pathogen persistence. Even when antibiotic therapy is effective and clears the pathogen, infected tissue often fails to reach *restitutio ad integrum*, leading to the formation of tissue scars. Such tissue changes and non-resolving inflammation are reminiscent of the disease processes in cancer [38]. In fact, many types of cancer are associated with infectious diseases, with several pathogens classified as Group 1 carcinogens so far [39–41]. We will discuss how MDSCs affect progression of various infections, including tuberculosis (TB), staphylococcal infections, viral hepatitis, immunodeficiency syndromes, chronic parasitic infections, and fungal disorders (Supplementary Table 1) (Fig. 1). In addition, we will discuss examples in which MDSC-driven effects have been associated with pathogen-induced carcinogenesis.

An example of a chronic bacterial infection in which MDSCs play an important role is active TB, which results predominantly from inefficient T-cell responses. Increased frequencies of MDSCs are present in pleural fluids from patients with pulmonary TB [42–44], and MDSCs isolated from the blood of TB patients suppress T-cell function [42, 43], secrete abundant IL-1 $\beta$  and IL-6 [42], and correlate with high NO levels [42, 44]. Peripheral MDSCs increase in cases of recent, but not remote infection, and a reduction in their frequencies is observed after treatment [43, 44], suggesting that the expansion of MDSCs correlates with increased bacterial burdens. These findings have been recapitulated in the mouse model of TB, in which MDSCs are found in multiple tissues in infected mice [45, 46]. These cells harbor *Mycobacterium tuberculosis* (*M. tuberculosis*), and may thus provide a niche for *M. tuberculosis* survival. Furthermore, they release both pro-inflammatory (IL-6, IL-1) and anti-inflammatory (IL-10) cytokines while exerting suppressive effects on T cells [45], including restriction of IFN- $\gamma$  production via NO-dependent mechanisms [46]. MDSCs may thus support immune evasion by promoting T-cell dysfunction and disease progression. Therefore, MDSCs are potential biomarkers of active TB and attractive targets for therapeutic intervention. Accordingly, different strategies used to deplete these cells during infection, either alone [45] or in combination with antibiotherapy [47], have resulted in improved disease outcomes in mice. MDSC depletion also improved disease outcome in *Staphylococcus aureus* (*S. aureus*) infection [48]. Gemcitabine delivery depleted PMN- and M-MDSCs and restored T-cell responses. *S. aureus* is frequently associated with orthopedic biofilms that subvert immune-mediated clearance, and in murine models, MDSCs represent the main cellular infiltrate in biofilms. Their abundance inversely correlates with T-cell activity and contributes to the chronicity of infection. Antibody-mediated depletion of biofilm MDSCs, which had increased Arg1, NOS2, and



**Fig. 1** Suppressive mechanisms of MDSCs in infection. MDSC subsets exhibit suppressive activities in various infections. Enzymatic pathways and secreted and cell-surface molecules controlling MDSC function are depicted in the context of specific pathogens. The target

cells and consequences of MDSC activities are indicated for each infectious agent. Suggested host-beneficial and detrimental effects of MDSCs are displayed color-coded, in green and red colors, respectively

IL-10 expression compared to spleen cells, improved bacterial clearance by augmenting pro-inflammatory cytokine release by monocytes and macrophages [48].

MDSCs may also support oncogenic transformation in chronic infections with bacterial pathogens that can cause colorectal and gastric cancer. In a murine model, infection with *Helicobacter felis* (*H. felis*) caused mobilization of PMN-MDSCs to the gastric mucosa and subsequent tissue metaplasia, a precursor of cancer [49]. PMN-MDSCs were also associated with intestinal metaplasia in human stomach tissue from *Helicobacter pylori*-infected individuals. Similarly, the gut commensal and candidate pathogen enterotoxigenic *Bacteroides fragilis* (ETBF) induced accumulation of MDSCs and colon carcinogenesis in a mouse model

of colorectal cancer [50]. In this study, sorted M-MDSCs displayed higher immunosuppressive activity than PMN-MDSC in *ex vivo* assays.

In viral infections, MDSCs support the establishment of chronicity. This has been elegantly demonstrated in kinetics experiments with different strains of lymphocytic choriomeningitis virus (LCMV). Comparable levels of MDSC expansion were observed during the first week of LCMV infection with the Armstrong (Arm) strain, which leads to acute resolving infection, and with clone 13 (C13), which develops into a chronic infection [51]. However, only C13 infection led to sustained high numbers of suppressive M-MDSCs in infected organs. C-C chemokine receptor (CCR)2-deficiency, which diminished the mobilization of monocytic cells, or

antibody depletion of Gr<sup>1+</sup> cells led to enhanced LCMV-specific T-cell cytokine responses in C13-infected mice, suggesting that expansion of suppressive M-MDSCs facilitated the establishment of chronicity [51]. A detailed analysis of MDSC during chronic infection with LP-BM5 retrovirus, which causes murine acquired immunodeficiency, has also provided evidence for M-MDSC-mediated downregulation of CD4<sup>+</sup> T-cell and B-cell responses [52].

HIV induces concomitant immune-regulatory and inflammatory mechanisms that drive chronic viral persistence and disease progression [53, 54]. Several studies have quantified MDSC frequencies in different phases of HIV infection and investigated their interplay with anti-viral immune responses. In patients with primary or chronic HIV-1 infection, expansion of PMN-MDSCs with enhanced expression of PD-L1 was observed early during the primary immune response [55]. *In vitro*, PD-L1 blockade with specific antibodies attenuated the inhibitory function of patient MDSCs co-cultured with CD8<sup>+</sup> T cells, suggesting that PD-L1 forms part of their suppressive arsenal. Chronically HIV-1-infected patients showed increased levels of PMN-MDSCs that expressed IL-4 receptor alpha (IL-4R $\alpha$ ), and this positively correlated with the viral load, inversely associated with the CD4<sup>+</sup> T-cell count and rapidly changed upon anti-retroviral therapy [56]. *In vitro*, MDSCs inhibited the proliferation of CD8<sup>+</sup> T cells from both healthy donors and HIV controllers (HIV-1-infected individuals able to control plasma viral load in the absence of therapy), and induced expansion of Tregs from HIV controllers. Another mechanism proposed for PMN-MDSC-mediated suppression in HIV-1 patients is their capability to inhibit CD3 $\zeta$  expression by cell-to-cell contact [57]. Increased frequencies of M-MDSCs have also been detected in HIV-1 patients despite effective anti-retroviral therapy [58]. The suppressive activity of these cells is mediated by Arg1 and cell-to-cell contact, but their specific contribution to disease pathophysiology in HIV-1 infection remains elusive. The simian immunodeficiency virus (SIV)-macaque model recapitulates the pathogenesis of HIV infection in humans and is, therefore, widely used to study the physiopathology of AIDS. In a recent study, SIV infection induced the expansion of CD14<sup>hi</sup>CD16<sup>-</sup>CCR2<sup>lo</sup> M-MDSCs that efficiently suppressed proliferation of CD8<sup>+</sup> T cells, but not of CD4<sup>+</sup> T cells [59]. Like in humans, anti-retroviral therapy of infected macaques led to contraction of MDSCs. Low copy numbers of SIV DNA were found in MDSCs of infected macaques, indicating that these cells could constitute a viral reservoir. In a follow-up study, PMN-MDSCs expanded after interruption of anti-retroviral therapy in the chronic phase of SIV infection. At all stages of infection, isolated PMN-MDSCs were able to suppress T-cell proliferation [60]. Despite clear evidence that MDSCs are induced in HIV/SIV infection and that they can inhibit T-cell responses, further studies are required to better characterize

the dynamics and role of different MDSC subsets in the tissues, where immune responses and inflammatory processes take place. Because of their immunosuppressive activity, MDSCs may constitute a reservoir for pathogens, and their permissiveness to HIV infection should be investigated.

M-MDSC frequencies are also significantly higher in patients with chronic HCV infection compared to healthy donors [6, 7, 61, 62] or patients receiving anti-viral therapy [61, 62]. MDSC-induced suppression in HCV infection has often been associated with expression of IL-10 and Arg1 [6, 61, 62]. M-MDSC frequency was found to positively correlate with HCV RNA levels [7, 61, 62] and Treg expansion [7]. Despite strong evidence that MDSCs contribute to T-cell impairment, which affects viral clearance in chronic HCV infection, one study has challenged this notion by reporting no differences in the frequencies of M-MDSCs and PMN-MDSCs between chronically infected HCV patients and healthy individuals and a lack of correlation between these cells and the viral load [63]. In chronic HBV infection, the M-MDSC population expands [10, 64] and M-MDSC frequencies correlate positively with HbsAg serum levels [10]. *In vitro*, MDSCs decreased HBV-specific CD8<sup>+</sup> T-cell responses via PD-1-dependent secretion of IL-10 [64]. In a mouse model of chronic HBV infection, forced maturation of MDSCs by delivery of all-trans retinoic acid [ATRA] limited viral replication [10]. In this model, M-MDSCs were more effective at suppressing T cells than PMN-MDSCs [65]. Their accumulation in the liver was driven by  $\gamma\delta$  T cells and led to CD8<sup>+</sup> T-cell exhaustion [66]. In contrast to the findings in mice, higher PMN-MDSC and not M-MDSC frequencies were found in a chronic HBV cohort [67]. PMN-MDSCs transiently expanded in acute resolving HBV infection and contracted prior to acute liver injury. In persistent infection, Arg-expressing PMN-MDSCs increased predominantly in phases characterized by HBV replication without immunopathology and accumulated in the liver, suggesting that PMN-MDSCs may restrict liver inflammation [67]. MDSC expansion during HBV infection could, therefore, prevent immunopathology at the cost of promoting chronicity. Whether distinct MDSC subtypes drive such dual outcomes needs further investigation.

Besides favoring chronicity, MDSC abundance correlates with the clinical outcome in several virus-associated malignancies. Epstein Barr virus (EBV) is the most growth-transforming pathogen in humans and, accordingly, is associated with human malignancies, mostly of B cell or epithelial cell origin [68]. In Hodgkin's lymphoma, which is EBV-associated, increased numbers of MDSCs in the blood were prognostic of a worse clinical outcome [69]. M-MDSCs were also found in EBV-associated extranodal natural killer NK/T-cell lymphomas [70]. In this study, their suppressive function was dependent on NOS2, Arg1, and ROS activities

and correlated with elevated expression of immune suppressive cytokines and an increase in Tregs. Several viral factors expressed by tumor cells may trigger expansion of functional MDSCs, as proposed in studies on EBV-associated nasopharyngeal carcinomas. For example, latent membrane protein 1-mediated glycolysis triggers the activation of p65 and the inflammasome, leading to the production of cytokines critical for MDSC expansion [71].

MDSCs also accumulate in chronic parasitic infections, which are commonly associated with the generation of Th2 and Treg responses [72]. *Schistosoma japonicum* antigens, for example, enhanced the expansion and suppressive activity of MDSCs [73]. In this model, immunosuppression was mediated through upregulation of NADPH oxidase subunits and ROS production. MDSCs isolated from *Heligmosomoides polygyrus* (*H. polygyrus*)-infected mice, in contrast, used an NO-dependent mechanism for immunosuppression [74]. Adoptive transfer of these cells promoted chronic infection with increased worm burdens and egg production. Like macrophages, M-MDSCs may be both classically and alternatively activated depending on their exposure to Th1 or Th2 cytokines and many helminths induce mixed Th1/Th2 responses, at least in certain phases of infection [75]. Following implantation with the cestode *T. crassiceps*, IL-4/IL-13 signaling was critical for gradual expansion of MDSCs in the peritoneal cavity and acquisition of an alternatively activated phenotype. These cells suppressed T-cell proliferation through mechanisms that switched from NO secretion at the early stages of infection to a combination of Arg activity, ROS production and generation of peroxisome proliferator-activated receptor gamma (PPAR- $\gamma$ ) ligands via 12/15-lipoxygenase (LOX) activity in the late phase of infection [76]. These results suggest that the mechanisms used by MDSCs to limit anti-parasitic adaptive responses may depend of the phase of infection.

The role of MDSCs in chronic infections with other pathogens such as protozoan parasites and fungi has also been investigated. During experimental leishmaniasis, resistant C57BL/6 mice accumulated MDSCs which suppressed parasite-specific T-cell proliferation, but not cytokine release [77]. MDSCs killed *Leishmania major* (*L. major*) parasites in an NO-dependent manner and enhanced parasite clearance in skin lesions despite decreased parasite-specific T-cell proliferation, suggesting that MDSCs enhanced resistance to *L. major* [77]. In agreement with these observations, genetically susceptible BALB/c mice exhibited a reduced ability to recruit CD11b<sup>+</sup>Ly6C<sup>hi</sup> cells to the site of *L. major* infection compared to resistant C57BL/6 mice [78]. Thus, genetic conditioning of MDSC function could contribute to disease resistance in murine inbred strains.


The fungal pathogen *Candida albicans* (*C. albicans*) induces a subset of PMN-MDSCs during infection in humans and mice [15]. In vitro, these cells inhibited T-cell

proliferation, and phagocytosed and killed fungi. In a mouse model of invasive *C. albicans* infection, adoptive transfer of PMN-MDSCs effectively dampened T and NK cell proliferation and improved mouse survival. Notably, different *Candida* species had differential capacities to induce in vitro PMN-MDSC expansion and subsequent suppressive activities [79]. *Aspergillus fumigatus* also elicited PMN-MDSCs [15], but adoptive transfer of MDSCs did not alter mice survival post-infection. The divergent effects of MDSCs in these fungal infections may have been due to the distinct animal models that were employed. *Aspergillus* infection was established in immunocompromised animals, whereas infection with *C. albicans* was performed in immunocompetent mice. MDSCs have also been studied in the context of *Pneumocystis pneumonia* (PcP), where they accumulated in the lungs of rodents upon infection and suppressed CD4<sup>+</sup> T-cell proliferation ex vivo [80]. Their frequency correlated with the severity of disease, and adoptive transfer of these cells into healthy mice caused lung damage. ATRA treatment of PcP-infected rats and mice led to diminished MDSC numbers and an increase in alveolar macrophages [81]. Co-culture studies have suggested that MDSCs disable alveolar macrophage function through PD-1/PD-L1 signaling, indicating that MDSCs can also interact with other myeloid cells [82].

In summary, during chronic infection, MDSCs can contribute to microbial persistence and pathogens often trigger and benefit from MDSC expansion. However, MDSCs may also promote pathogen killing by intrinsic effector mechanisms or prevent excessive tissue damage. Further investigations are required to determine the kinetics of MDSC subtypes and reveal how their compartmentalization to tissues or lesions influences the course of infections. MDSCs drive tissue metaplasia and are associated with a poor prognosis in cancer. Although it is poorly investigated, the genesis of MDSCs in such infections appears to be driven by prolonged inflammation, and possibly by microbial moieties. A comprehensive characterization of MDSCs in microbial-induced cancers is essential for the design of novel preventive and therapeutic strategies in this subgroup of malignancies.

## Targeting MDSCs by host-directed interventions for infectious diseases

Various strategies to target MDSCs can be envisaged, depending on whether these cells have a beneficial or detrimental role in the infection concerned (Fig. 2). In several chronic infections in which MDSC expansion limits protective immunity, depletion of MDSCs is able to reverse immunosuppression and improve disease outcome [45, 48]. In TB and SIV infection, such interventions may in addition remove pathogen reservoirs, as MDSCs can harbor these microbes [45, 83]. MDSCs can be targeted by (i) depletion;



**Fig. 2** Targeting MDSCs as part of host-directed interventions against infection. Four different strategies have been envisaged for manipulating MDSCs: maturation-induced ablation, depletion, interference with their suppressive activity and altering their genesis.

Specific drugs for each approach, as well as evidence from particular infectious diseases and the outcome of each immune therapy are summarized. Asterisk: successful method for depletion in mouse model

(ii) maturation-induced ablation; (iii) interfering with their production; and (iv) inhibition of their suppressive activities.

Antibody-mediated depletion of Gr1<sup>+</sup>Ly6G<sup>+</sup> MDSC-like cells has proven successful in experimental models of TB [45, 84, 85], staphylococcal disease [3, 48], and viral

infection [29, 51]. However, antibody depletion is impracticable in humans, because MDSCs lack unique surface markers, and frequencies and functions of related myeloid populations could be affected. Drug-induced depletion of MDSCs using cytotoxic agents such as gemcitabine and

denileukin diftitox has been used in proof-of-principle experiments in murine models of *S. aureus* infection [86] and as a host-directed therapy (HDT) complementing canonical chemotherapy in TB [47]. Ablating MDSCs by inducing maturation is a more attractive option for therapeutically reducing the numbers of these cells. Various classes of drugs can induce differentiation or maturation of MDSCs. ATRA, for example, which induces MDSC differentiation into dendritic cells and macrophages, has been successfully employed in mouse models of TB. In these studies, ATRA ablated MDSCs and restricted bacterial replication [45], especially when given as adjunct to TB chemotherapy [87]. In a mouse model of HBV infection, ATRA promoted the maturation of HBV-induced MDSCs, restored proliferation and IFN- $\gamma$  production of HBV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells from chronically infected patients and prevented viral replication [10].

Alternatively, differentiation of MDSCs can be achieved by the delivery of  $\beta$ -glucan or low doses of cyclic dinucleotides; strategies which have had beneficial effects in mouse models of cancer [16, 88]. A reduction in MDSCs can also be accomplished by the administration of ceramidase inhibitors, which induces apoptosis through ER stress and interference with autophagy [89]. More recently, activation of liver X receptors has proven to be efficient in inducing apoptosis of MDSCs and has been employed in preclinical models and in human trials for tumor immunotherapy [90]. Interfering with enzymatic pathways relevant for MDSC-induced suppression represents a complementary intervention for targeting these cells. Phosphodiesterase (PDE) (i.e., PDE5) inhibitors block MDSC suppression by limiting Arg1 and NOS2 expression, and are beneficial as a HDT in TB [91]. However, they may exhibit broad effects on other myeloid cells and additional pathways. Targeting the generation of MDSCs is possible with COX2 inhibitors, which block the synthesis of PGE2. This may explain the beneficial role of ibuprofen in a TB model characterized by increased MDSCs [92, 93]. In contrast to ablation, drug-induced generation of MDSCs has recently been reported. Delivery of finasteride boosts the genesis of suppressor cells [94] and may be employed in infections in which MDSCs are beneficial, for instance in acute sepsis or *Pseudomonas aeruginosa* (*P. aeruginosa*) infection [5, 25, 35]. Additional studies on the biology of MDSCs in infections are required to advance such HDTs into the clinic and to discover novel ways of targeting these cells therapeutically.

## General conclusions and future perspectives

The roles of MDSCs in fine-tuning the interplay between host and pathogen are being increasingly recognized. Like most myeloid cell subsets, MDSCs are endowed with plasticity. One of the major challenges in dissecting the roles

of MDSC subsets is that much of the research is based on a combination of correlation studies in vivo and functional assays ex vivo. In a study using genetically engineered mice in which either M-MDSC or PMN-MDSC were depleted, M-MDSCs were identified as the principle immunosuppressive MDSC population in the tumor microenvironment [27]. Before experiments using such genetic tools are performed in models of infection, including infections caused by tumorigenic microbes, current conclusions on the relative contributions of specific MDSC populations during infection need to be drawn cautiously.

MDSCs have nonetheless emerged as targets for HDTs for infectious diseases. The rapid development of antimicrobial resistance advances these cells in the pipeline for the development of novel therapies against drug-resistant microbes. Therapeutic targeting of MDSCs in infections with tumorigenic microbes, and the effect on tissue metaplasia, needs to be evaluated. Apart from their therapeutic potential, MDSCs have barely been investigated in the context of vaccination. Living organisms, PAMPs, adjuvants and inflammation trigger MDSCs generation. Thus, an understanding of whether and how MDSCs affect the success of immunizations is needed. This is particularly relevant for newborns and the elderly, as MDSC frequencies are raised in both age groups [95, 96]. Finally, the value of MDSCs as biomarkers and their benefits for stratification of patients further justifies accelerating research focused on the biology of MDSCs in infection and pathogen-associated malignancies.

**Acknowledgements** We thank Ronnie Grant (University of Edinburgh) for figure editing.

**Author contributions** Conceptualization and writing of the original draft: all authors. Figure design: AD, EG, TG-T, and AFV. Revisions and editing: AD, NEN, CG, and AFV. Supervision: AD and AFV. All authors approved the final version of this paper.

**Funding** This work was supported by European Cooperation in Science and Technology (COST) and the COST Action BM1404 Mye-EUNITER (<http://www.mye-euniter.eu>). COST is part of the European Union Framework Programme Horizon 2020. Estibaliz Glaría is supported by a fellowship from the University of Barcelona (Ajuts de Personal Investigador predoctoral en Formació, APIF); Thalia Garcia-Tellez is supported by the Institut Carnot Pasteur Maladie Infectieuses (ANR 11-CARN 017-01) as part of the Pasteur—Paris University (PPU) International PhD Program and by Sidaction.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflicts of interest.

## References

- Bronte V, Brandau S, Chen S-H et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun* 7:12150. <https://doi.org/10.1038/ncomms12150>
- Bruger AM, Dorhoi A, Esendagli G et al (2018) How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. *Cancer Immunol Immunother*. <https://doi.org/10.1007/s00262-018-2170-8>
- Skabytska Y, Wölbling F, Günther C et al (2014) Cutaneous innate immune sensing of toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. *Immunity* 41:762–775. <https://doi.org/10.1016/j.IMMUNI.2014.10.009>
- Arora M, Poe SL, Oriss TB et al (2010) TLR4/MyD88-induced CD11b+ Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung. *Mucosal Immunol* 3:578–593. <https://doi.org/10.1038/mi.2010.41>
- Rieber N, Brand A, Hector A et al (2013) Flagellin induces myeloid-derived suppressor cells: implications for *Pseudomonas aeruginosa* infection in cystic fibrosis lung disease. *J Immunol* 190:1276–1284. <https://doi.org/10.4049/jimmunol.1202144>
- Ren JP, Zhao J, Dai J et al (2016) Hepatitis C virus-induced myeloid-derived suppressor cells regulate T-cell differentiation and function via the signal transducer and activator of transcription 3 pathway. *Immunology* 148:377–386. <https://doi.org/10.1111/imm.12616>
- Zhai N, Li H, Song H et al (2017) Hepatitis C virus induces MDSCs-like monocytes through TLR2/PI3K/AKT/STAT3 signaling. *PLoS One* 12:e0170516. <https://doi.org/10.1371/journal.pone.0170516>
- Tacke RS, Lee H-C, Goh C et al (2012) Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. *Hepatology* 55:343–353. <https://doi.org/10.1002/hep.24700>
- Goh CC, Roggerson KM, Lee H-C et al (2016) Hepatitis C virus-induced myeloid-derived suppressor cells suppress NK cell IFN- $\gamma$  production by altering cellular metabolism via arginase-1. *J Immunol* 196:2283–2292. <https://doi.org/10.4049/jimmunol.1501881>
- Fang Z, Li J, Yu X et al (2015) Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection. *J Immunol* 195:4873–4883. <https://doi.org/10.4049/jimmunol.1501362>
- Garg A, Spector SA (2014) HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. *J Infect Dis* 209:441–451. <https://doi.org/10.1093/infdis/jit469>
- Dorhoi A, Du Plessis N (2018) Monocytic myeloid-derived suppressor cells in chronic infections. *Front Immunol* 8:1895. <https://doi.org/10.3389/fimmu.2017.01895>
- De Santo C, Salio M, Masri SH et al (2008) Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. *J Clin Invest* 118:4036–4048. <https://doi.org/10.1172/JCI36264>
- Jeisy-Scott V, Davis WG, Patel JR et al (2011) Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice. *PLoS One* 6:e25242. <https://doi.org/10.1371/journal.pone.0025242>
- Rieber N, Singh A, Öz H et al (2015) Pathogenic fungi regulate immunity by inducing neutrophilic myeloid-derived suppressor cells. *Cell Host Microbe* 17:507–514. <https://doi.org/10.1016/j.chom.2015.02.007>
- Albeituni SH, Ding C, Liu M et al (2016) Yeast-derived particulate  $\beta$ -glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation to APC in cancer. *J Immunol* 196:2167–2180. <https://doi.org/10.4049/jimmunol.1501853>
- Gomez-Garcia L, Lopez-Marin LM, Saavedra R et al (2005) Intact glycans from cestode antigens are involved in innate activation of myeloid suppressor cells. *Parasite Immunol* 27:395–405. <https://doi.org/10.1111/j.1365-3024.2005.00790.x>
- Terrazas LI, Walsh KL, Piskorska D et al (2001) The schistosome oligosaccharide lacto-*N*-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections. *J Immunol* 167:5294–5303
- Atochina O, Daly-Engel T, Piskorska D et al (2001) A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN- $\gamma$  and nitric oxide-dependent mechanism. *J Immunol* 167:4293–4302
- Wagner A, Schabussova I, Drinic M et al (2016) Oocyst-derived extract of *Toxoplasma gondii* serves as potent immunomodulator in a mouse model of birch pollen allergy. *PLoS One* 11:e0155081. <https://doi.org/10.1371/journal.pone.0155081>
- Ost M, Singh A, Peschel A et al (2016) Myeloid-derived suppressor cells in bacterial infections. *Front Cell Infect Microbiol* 6:37. <https://doi.org/10.3389/fcimb.2016.00037>
- Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol* 9:162–174. <https://doi.org/10.1038/nri2506>
- Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. *Nat Immunol* 19:108–119. <https://doi.org/10.1038/s41590-017-0022-x>
- Arocena AR, Onofrio LI, Pellegrini AV et al (2014) Myeloid-derived suppressor cells are key players in the resolution of inflammation during a model of acute infection. *Eur J Immunol* 44:184–194. <https://doi.org/10.1002/eji.201343606>
- Sander LE, Sackett SD, Dierssen U et al (2010) Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. *J Exp Med* 207:1453–1464. <https://doi.org/10.1084/jem.20091474>
- Ribechini E, Hutchinson JA, Hergovits S et al (2017) Novel GM-CSF signals via IFN- $\gamma$ R/IRF-1 and Akt/mTOR license monocytes for suppressor function. *Blood Adv* 1:947–960. <https://doi.org/10.1182/bloodadvances.2017006858>
- Haverkamp JM, Smith AM, Weinlich R et al (2014) Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. *Immunity* 41:947–959. <https://doi.org/10.1016/j.immuni.2014.10.020>
- Wang C, Zhang N, Qi L et al (2017) Myeloid-derived suppressor cells inhibit T follicular helper cell immune response in Japanese encephalitis virus infection. *J Immunol* 199:3094–3105. <https://doi.org/10.4049/jimmunol.1700671>
- Drabczyk-Pluta M, Werner T, Hoffmann D et al (2017) Granulocytic myeloid-derived suppressor cells suppress virus-specific CD8<sup>+</sup> T cell responses during acute friend retrovirus infection. *Retrovirology* 14:42. <https://doi.org/10.1186/s12977-017-0364-3>
- Voisin M-B, Buzoni-Gatel D, Bout D, Velge-Roussel F (2004) Both expansion of regulatory GR1+ CD11b+ myeloid cells and anergy of T lymphocytes participate in hyporesponsiveness of the lung-associated immune system during acute toxoplasmosis. *Infect Immun* 72:5487–5492. <https://doi.org/10.1128/IAI.72.9.5487-5492.2004>
- Darcy CJ, Minigo G, Piera KA et al (2014) Neutrophils with myeloid derived suppressor function deplete arginine and constrain T

- cell function in septic shock patients. *Crit Care* 18:R163. <https://doi.org/10.1186/cc14003>
32. Janols H, Bergenfelz C, Allaoui R et al (2014) A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in Gram-positive cases. *J Leukoc Biol* 96:685–693. <https://doi.org/10.1189/jlb.5HI0214-074R>
  33. Uhel F, Azzaoui I, Grégoire M et al (2017) Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in patients with sepsis. *Am J Respir Crit Care Med* 196:315–327. <https://doi.org/10.1164/rccm.201606-1143OC>
  34. Delano MJ, Scumpia PO, Weinstein JS et al (2007) MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. *J Exp Med* 204:1463–1474. <https://doi.org/10.1084/jem.20062602>
  35. Poe SL, Arora M, Oriss TB et al (2013) STAT1-regulated lung MDSC-like cells produce IL-10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia. *Mucosal Immunol* 6:189–199. <https://doi.org/10.1038/mi.2012.62>
  36. Cuervo H, Guerrero NA, Carbajosa S et al (2011) Myeloid-derived suppressor cells infiltrate the heart in acute *Trypanosoma cruzi* infection. *J Immunol* 187:2656–2665. <https://doi.org/10.4049/jimmunol.1002928>
  37. Sanmarco LM, Visconti LM, Eberhardt N et al (2016) IL-6 improves the nitric oxide-induced cytotoxic CD8+ T cell dysfunction in human chagas disease. *Front Immunol* 7:626. <https://doi.org/10.3389/fimmu.2016.00626>
  38. Nathan C, Ding A (2010) Nonresolving Inflammation. *Cell* 140:871–882. <https://doi.org/10.1016/j.cell.2010.02.029>
  39. White MK, Pagano JS, Khalili K (2014) Viruses and human cancers: a long road of discovery of molecular paradigms. *Clin Microbiol Rev* 27:463–481. <https://doi.org/10.1128/CMR.00124-13>
  40. Chang AH, Parsonnet J (2010) Role of bacteria in oncogenesis. *Clin Microbiol Rev* 23:837–857. <https://doi.org/10.1128/CMR.00012-10>
  41. van Tong H, Brindley PJ, Meyer CG, Velavan TP (2017) Parasite infection, carcinogenesis and human malignancy. *EBioMedicine* 15:12–23. <https://doi.org/10.1016/j.ebiom.2016.11.034>
  42. Yang B, Wang X, Jiang J et al (2014) Identification of CD244-expressing myeloid-derived suppressor cells in patients with active tuberculosis. *Immunol Lett* 158:66–72. <https://doi.org/10.1016/j.imlet.2013.12.003>
  43. du Plessis N, Loebenberg L, Kriel M et al (2013) Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent *Mycobacterium tuberculosis* infection suppresses T-cell function. *Am J Respir Crit Care Med* 188:724–732. <https://doi.org/10.1164/rccm.201302-0249OC>
  44. El Daker S, Sacchi A, Tempestilli M et al (2015) Granulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level. *PLoS One* 10:e0123772. <https://doi.org/10.1371/journal.pone.0123772>
  45. Knaul JK, Jörg S, Oberbeck-Mueller D et al (2014) Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. *Am J Respir Crit Care Med* 190:1053–1066. <https://doi.org/10.1164/rccm.201405-0828OC>
  46. Tsiganov EN, Verbina EM, Radaeva TV et al (2014) Gr-1dim-CD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. *J Immunol* 192:4718–4727. <https://doi.org/10.4049/jimmunol.1301365>
  47. Gupta S, Cheung L, Pokkali S et al (2017) Suppressor cell-depleting immunotherapy with denileukin diftitox is an effective host-directed therapy for tuberculosis. *J Infect Dis* 215:1883–1887. <https://doi.org/10.1093/infdis/jix208>
  48. Heim CE, Vidlak D, Scherr TD et al (2014) Myeloid-derived suppressor cells contribute to *Staphylococcus aureus* orthopedic biofilm infection. *J Immunol* 192:3778–3792. <https://doi.org/10.4049/jimmunol.1303408>
  49. Ding L, Hayes MM, Photenhauer A et al (2016) Schlafen 4–expressing myeloid-derived suppressor cells are induced during murine gastric metaplasia. *J Clin Invest* 126:2867–2880. <https://doi.org/10.1172/JCI82529>
  50. Thiele Orberg E, Fan H, Tam AJ et al (2017) The myeloid immune signature of enterotoxigenic *Bacteroides fragilis*-induced murine colon tumorigenesis. *Mucosal Immunol* 10:421–433. <https://doi.org/10.1038/mi.2016.53>
  51. Norris BA, Uebelhoer LS, Nakaya HI et al (2013) Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity. *Immunity* 38:309–321. <https://doi.org/10.1016/j.immuni.2012.10.022>
  52. Green KA, Cook WJ, Green WR (2013) Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency. *J Virol* 87:2058–2071. <https://doi.org/10.1128/JVI.01547-12>
  53. Alaoui L, Palomino G, Zurawski S et al (2017) Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs. *Cell Mol Life Sci* 1–17. <https://doi.org/10.1007/s00018-017-2712-9>
  54. Huot N, Rasclé P, Garcia-Tellez T et al (2016) Innate immune cell responses in non pathogenic versus pathogenic SIV infections. *Curr Opin Virol* 19:37–44. <https://doi.org/10.1016/j.coviro.2016.06.011>
  55. Zhang Z-N, Yi N, Zhang T-W et al (2017) Myeloid-derived suppressor cells associated with disease progression in primary HIV infection. *JAIDS J Acquir Immune Defic Syndr* 76:200–208. <https://doi.org/10.1097/QAI.0000000000001471>
  56. Vollbrecht T, Stirner R, Tufman A et al (2012) Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. *AIDS* 26:F31–F37. <https://doi.org/10.1097/QAD.0b013e32832854b43f>
  57. Tumino N, Turchi F, Meschi S et al (2015) In HIV-positive patients, myeloid-derived suppressor cells induce T-cell anergy by suppressing CD3  $\zeta$  expression through ELF-1 inhibition. *AIDS* 29:2397–2407. <https://doi.org/10.1097/QAD.0000000000000871>
  58. Qin A, Cai W, Pan T et al (2013) Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. *J Virol* 87:1477–1490. <https://doi.org/10.1128/JVI.01759-12>
  59. Gama L, Shirk EN, Russell JN et al (2012) Expansion of a subset of CD14<sup>high</sup>CD16<sup>neg</sup>CCR2<sup>low</sup>/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection. *J Leukoc Biol* 91:803–816. <https://doi.org/10.1189/jlb.1111579>
  60. Dross SE, Munson PV, Kim SE et al (2017) Kinetics of myeloid-derived suppressor cell frequency and function during simian immunodeficiency virus infection, combination antiretroviral therapy, and treatment interruption. *J Immunol* 198:757–766. <https://doi.org/10.4049/jimmunol.1600759>
  61. Cai W, Qin A, Guo P et al (2013) Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. *J Clin Immunol* 33:798–808. <https://doi.org/10.1007/s10875-012-9861-2>
  62. Zeng Q-L, Yang B, Sun H-Q et al (2014) Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR  $\zeta$  chain expression on CD8(+) T cells in chronic hepatitis C patients. *Mol Cells* 37:66–73. <https://doi.org/10.14348/molcells.2014.2282>
  63. Nonnenmann J, Stirner R, Roeder J et al (2014) Lack of significant elevation of myeloid-derived suppressor cells in peripheral

- blood of chronically hepatitis C virus-infected individuals. *J Virol* 88:7678–7682. <https://doi.org/10.1128/JVI.00113-14>
64. Huang A, Zhang B, Yan W et al (2014) Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10. *J Immunol* 193:5461–5469. <https://doi.org/10.4049/jimmunol.1400849>
  65. Chen S, Akbar SMF, Abe M et al (2011) Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. *Clin Exp Immunol* 166:134–142. <https://doi.org/10.1111/j.1365-2249.2011.04445.x>
  66. Kong X, Sun R, Chen Y et al (2014)  $\gamma\delta$ T cells drive myeloid-derived suppressor cell-mediated CD8<sup>+</sup> T cell exhaustion in hepatitis B virus-induced immunotolerance. *J Immunol* 193:1645–1653. <https://doi.org/10.4049/jimmunol.1303432>
  67. Pallett LJ, Gill US, Quaglia A et al (2015) Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. *Nat Med* 21:591–600. <https://doi.org/10.1038/nm.3856>
  68. Cesarman E (2014) Gammaherpesviruses and lymphoproliferative disorders. *Annu Rev Pathol Mech Dis* 9:349–372. <https://doi.org/10.1146/annurev-pathol-012513-104656>
  69. Romano A, Parrinello NL, Vetro C et al (2015) Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. *Br J Haematol* 168:689–700. <https://doi.org/10.1111/bjh.13198>
  70. Zhang H, Li Z-L, Ye S-B et al (2015) Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator. *Cancer Immunol Immunother* 64:1587–1599. <https://doi.org/10.1007/s00262-015-1765-6>
  71. Cai T-T, Ye S-B, Liu Y-N et al (2017) LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. *PLoS Pathog* 13:e1006503. <https://doi.org/10.1371/journal.ppat.1006503>
  72. Maizels RM, McSorley HJ (2016) Regulation of the host immune system by helminth parasites. *J Allergy Clin Immunol* 138:666–675. <https://doi.org/10.1016/j.jaci.2016.07.007>
  73. Yang Q, Qiu H, Xie H et al (2017) A *Schistosoma japonicum* infection promotes the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. *J Immunol* 198:4716–4727. <https://doi.org/10.4049/jimmunol.1601860>
  74. Valanparambil RM, Tam M, Jardim A et al (2017) Primary Heligmosomoides polygyrus bakeri infection induces myeloid-derived suppressor cells that suppress CD4<sup>+</sup> Th2 responses and promote chronic infection. *Mucosal Immunol* 10:238–249. <https://doi.org/10.1038/mi.2016.36>
  75. Van Ginderachter JA, Beschin A, De Baetselier P, Raes G (2010) Myeloid-derived suppressor cells in parasitic infections. *Eur J Immunol* 40:2976–2985. <https://doi.org/10.1002/eji.201040911>
  76. Brys L, Beschin A, Raes G et al (2005) Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. *J Immunol* 174:6095–6104. <https://doi.org/10.4049/jimmunol.174.10.6095>
  77. Pereira WF, Ribeiro-Gomes FL, Guillermo LVC et al (2011) Myeloid-derived suppressor cells help protective immunity to Leishmania major infection despite suppressed T cell responses. *J Leukoc Biol* 90:1191–1197. <https://doi.org/10.1189/jlb.1110608>
  78. Schmid M, Zimara N, Wege AK, Ritter U (2014) Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice. *Eur J Immunol* 44:3295–3306. <https://doi.org/10.1002/eji.201344335>
  79. Singh A, Lelis F, Braig S et al (2016) Differential regulation of myeloid-derived suppressor cells by *Candida* species. *Front Microbiol* 7:1624. <https://doi.org/10.3389/fmicb.2016.01624>
  80. Zhang C, Lei G-S, Shao S et al (2012) Accumulation of myeloid-derived suppressor cells in the lungs during *Pneumocystis pneumonia*. *Infect Immun* 80:3634–3641. <https://doi.org/10.1128/IAI.00668-12>
  81. Lei G-S, Zhang C, Shao S et al (2013) All-trans retinoic acid in combination with primaquine clears pneumocystis infection. *PLoS One* 8:e53479. <https://doi.org/10.1371/journal.pone.0053479>
  82. Lei G-S, Zhang C, Lee C-H (2015) Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during *Pneumocystis pneumonia*. *Infect Immun* 83:572–582. <https://doi.org/10.1128/IAI.02686-14>
  83. Sui Y, Frey B, Wang Y et al (2017) Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. *PLoS Pathog* 13:e1006395. <https://doi.org/10.1371/journal.ppat.1006395>
  84. Keller C, Hoffmann R, Lang R et al (2006) Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. *Infect Immun* 74:4295–4309. <https://doi.org/10.1128/IAI.00057-06>
  85. Eruslanov EB, Lyadova IV, Kondratieva TK et al (2005) Neutrophil responses to *Mycobacterium tuberculosis* infection in genetically susceptible and resistant mice. *Infect Immun* 73:1744–1753. <https://doi.org/10.1128/IAI.73.3.1744-1753.2005>
  86. Tebartz C, Horst SA, Sparwasser T et al (2015) A major role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immunosuppression during *Staphylococcus aureus* infection. *J Immunol* 194:1100–1111. <https://doi.org/10.4049/jimmunol.1400196>
  87. Mourik BC, Leenen PJM, de Knecht GJ et al (2017) Immunotherapy added to antibiotic treatment reduces relapse of disease in a mouse model of tuberculosis. *Am J Respir Cell Mol Biol* 56:233–241. <https://doi.org/10.1165/rcmb.2016-0185OC>
  88. Chandra D, Quispe-Tintaya W, Jahangir A et al (2014) STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. *Cancer Immunol Res* 2:901–910. <https://doi.org/10.1158/2326-6066.CIR-13-0123>
  89. Liu F, Li X, Lu C et al (2016) Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. *Oncotarget* 7:83907–83925. <https://doi.org/10.18632/oncotarget.13438>
  90. Tavazoie MF, Pollack I, Tanquero R et al (2018) LXR/ApoE activation restricts innate immune suppression in cancer. *Cell* 172:825–840.e18. <https://doi.org/10.1016/j.cell.2017.12.026>
  91. Ahidjo BA, Bishai WR (2016) Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis. *EBioMedicine* 4:7–8. <https://doi.org/10.1016/j.ebiom.2016.02.016>
  92. Obregón-Henao A, Henao-Tamayo M, Orme IM, Ordway DJ (2013) Gr1(int)CD11b<sup>+</sup> myeloid-derived suppressor cells in *Mycobacterium tuberculosis* infection. *PLoS One* 8:e80669. <https://doi.org/10.1371/journal.pone.0080669>
  93. Vilaplana C, Marzo E, Tapia G et al (2013) Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. *J Infect Dis* 208:199–202. <https://doi.org/10.1093/infdis/jit152>
  94. Zhang S, Wu K, Liu Y et al (2016) Finasteride Enhances the generation of human myeloid-derived suppressor cells by up-regulating the COX2/PGE2 pathway. *PLoS One* 11:e0156549. <https://doi.org/10.1371/journal.pone.0156549>

95. Rieber N, Gille C, Köstlin N et al (2013) Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses. *Clin Exp Immunol* 174:45–52. <https://doi.org/10.1111/cei.12143>
96. Flores RR, Clauson CL, Cho J et al (2017) Expansion of myeloid-derived suppressor cells with aging in the bone marrow of mice through a NF- $\kappa$ B-dependent mechanism. *Aging Cell* 16:480–487. <https://doi.org/10.1111/acel.12571>

## Affiliations

Anca Dorhoi<sup>1,2,3</sup> · Estibaliz Glaría<sup>4,5</sup>  · Thalia Garcia-Tellez<sup>6</sup>  · Natalie E. Nieuwenhuizen<sup>3</sup>  · Gennadiy Zelinsky<sup>7</sup>  · Benoit Favier<sup>8</sup>  · Anurag Singh<sup>9</sup>  · Jan Ehrchen<sup>10</sup> · Cornelia Gujer<sup>11</sup>  · Christian Münz<sup>11</sup>  · Margarida Saraiva<sup>12,13</sup>  · Yahya Sohrabi<sup>14,15</sup>  · Ana E. Sousa<sup>16</sup>  · Peter Delpitte<sup>17</sup>  · Michaela Müller-Trutwin<sup>6</sup>  · Annabel F. Valledor<sup>4,5</sup> 

<sup>1</sup> Institute of Immunology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Südufer 10, 17493 Greifswald, Insel Riems, Germany

<sup>2</sup> Faculty of Mathematics and Natural Sciences, University of Greifswald, Greifswald, Germany

<sup>3</sup> Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany

<sup>4</sup> Nuclear Receptor Group, Department of Cell Biology, Physiology and Immunology, School of Biology, University of Barcelona, Av. Diagonal, 643, 3rd floor, 08028 Barcelona, Spain

<sup>5</sup> Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain

<sup>6</sup> Institut Pasteur, HIV Inflammation and Persistence Unit, Paris, France

<sup>7</sup> Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

<sup>8</sup> Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, CEA, Université Paris Sud 11, INSERM U1184, IBJF, Fontenay-aux-Roses, France

<sup>9</sup> University Children's Hospital and Interdisciplinary Center for Infectious Diseases, University of Tübingen, Tübingen, Germany

<sup>10</sup> Department of Dermatology, University Hospital Münster, Münster, Germany

<sup>11</sup> Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zurich, Switzerland

<sup>12</sup> i3S-Instituto de Investigação e Inovação em Saúde, Porto, Portugal

<sup>13</sup> IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal

<sup>14</sup> Molecular and Translational Cardiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany

<sup>15</sup> Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic

<sup>16</sup> Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

<sup>17</sup> Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium